Curadoria · Saúde

Big pharma

Por InspectStocksPublished 14 de out. de 202613 companies0 follower

The largest drugmakers, selling prescription medicines worldwide.

Agrupadas com a ajuda de um modelo de IA e revisadas pelos nossos editores. A linha abaixo de cada empresa diz por que ela está aqui.

Download image

Cartões Níveis

Os preços das ações são o fechamento de 11 de nov. de 2026, do feed da bolsa IEX.

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34,0%

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap US$ 1,35TP/E 46,67
US$ 1.437,79+42,2%1Y
Since added +23,2%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 86,5B+45,5%
Profit
US$ 27,6B+49,8%
Free cash flow
US$ 19,7B+112,1%
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap US$ 674,9BP/E 42,54
US$ 280,34+47,5%1Y
Since added +12,8%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Misto
Revenue
US$ 99,3B+7,8%
Profit
US$ 16,1B-35,9%
Free cash flow
US$ 20,6B+5,1%
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap US$ 521,2BP/E 50,75
US$ 294,87+30,2%1Y
Since added +7,5%
B+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 66B+10,7%
Profit
US$ 10,3B+333,1%
Free cash flow
US$ 18,9B-4,1%
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap US$ 362,9BP/E 150,20
US$ 147,20+65,7%1Y
Since added +3,7%
A
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Sólida
Getting better
Misto
Revenue
US$ 67,4B+4,9%
Profit
US$ 2,5B-87,1%
Free cash flow
US$ 14,7B+13,0%
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap US$ 306BSem P/L (prejuízo operacional)
US$ 160,36+23,6%1Y
Since added +12,6%
A
Crescimento e caixa
Crescendo com força
Business quality
Mista
Getting better
Melhorando com força
Revenue
US$ 56,7B+9,6%
Profit
-US$ 46MNo comparable year
Free cash flow
US$ 17,6B+8,3%
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap US$ 289,7BP/E 28,36
US$ 185,49+115,2%1Y
Since added +19,0%
B+
Crescimento e caixa
Crescendo com força
Business trend
Desacelerando
Business quality
Forte
Getting better
Melhorando com força
Revenue
US$ 62,4B+7,3%
Profit
US$ 10,2B+45,3%
Free cash flow
US$ 11,8B+18,4%
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap US$ 182,8BP/E 11,84
US$ 41,10-15,4%1Y
Since added +8,0%
C+
Crescimento e caixa
Crescendo
Business trend
Acelerando
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 50,3B+5,7%
Profit
US$ 17,1B+9,1%
Free cash flow
US$ 8,9B-20,1%
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap US$ 167,9BP/E 42,07
US$ 29,45+21,4%1Y
Since added +3,8%
C
Crescimento e caixa
Crescendo com força
Business trend
Encolhendo
Business quality
Sólida
Getting better
Misto
Revenue
US$ 63,6B+1,3%
Profit
US$ 4B-59,0%
Free cash flow
US$ 11,8B+13,6%
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap US$ 128,6BP/E 13,95
US$ 62,92+34,0%1Y
Since added +11,0%
C+
Crescimento e caixa
Crescendo
Business trend
Estável
Business quality
Forte
Getting better
Melhorando com força
Revenue
US$ 50B+4,2%
Profit
US$ 9,2B+53,1%
Free cash flow
US$ 9,3B-39,3%
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap US$ 59,1BP/E 6,81
US$ 48,43-3,0%1Y
Since added +23,9%
B
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 53,5B+11,6%
Profit
US$ 4,7B-54,2%
Free cash flow
US$ 8,1B+22,5%
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap US$ 109,2BP/E 13,60
US$ 50,60+8,9%1Y
Since added +9,3%
A+
Crescimento e caixa
Crescendo com força
Business quality
Forte
Getting better
Melhorando com força
Revenue
US$ 43,8B+4,1%
Profit
US$ 7,7B+122,0%
Free cash flow
US$ 8,6B+24,0%
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap US$ 253,2BP/E 27,14
US$ 468,13+43,1%1Y
Since added +13,4%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 38,9B+8,2%
Profit
US$ 9,4B+34,1%
Free cash flow
US$ 9,6B-17,0%
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap US$ 33,5BP/E 48,79
US$ 20,86+50,1%1Y
Since added +12,5%
A
Crescimento e caixa
Crescendo com força
Business quality
Mista
Getting better
Misto
Revenue
US$ 29,8BNo comparable year
Profit
US$ 259,4MNo comparable year
Free cash flow
US$ 5,5B+1,1%
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.